Figure 6From: Targeted delivery of CD40L promotes restricted activation of antigen-presenting cells and induction of cancer cell deathscFv-dependent signaling by scFv:CD40L fusion proteins. A BJAB, B Raji and C Z138 B leukemia cell lines were treated for 5 days with 1 μg/mL Rituximab, anti-CD20:CD40L, irrelevant IgG1 control antibody, or anti-EpCAM:CD40L and cell death assessed by loss of mitochondrial membrane potential.Back to article page